WO1990015140A1 - Production of ibdv vp2 in highly immunogenic form - Google Patents
Production of ibdv vp2 in highly immunogenic form Download PDFInfo
- Publication number
- WO1990015140A1 WO1990015140A1 PCT/AU1990/000224 AU9000224W WO9015140A1 WO 1990015140 A1 WO1990015140 A1 WO 1990015140A1 AU 9000224 W AU9000224 W AU 9000224W WO 9015140 A1 WO9015140 A1 WO 9015140A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ibdv
- expression
- pyelc5
- strain
- clone
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 title description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 58
- 241000702626 Infectious bursal disease virus Species 0.000 claims abstract description 57
- 239000002773 nucleotide Substances 0.000 claims abstract description 16
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 16
- 101710172711 Structural protein Proteins 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 7
- 229920001184 polypeptide Polymers 0.000 claims abstract description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 57
- 239000013598 vector Substances 0.000 claims description 18
- 239000013612 plasmid Substances 0.000 claims description 17
- 210000004899 c-terminal region Anatomy 0.000 claims description 13
- 229960005486 vaccine Drugs 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 11
- 230000004927 fusion Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000010367 cloning Methods 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 241001138401 Kluyveromyces lactis Species 0.000 claims description 8
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 7
- 108020004511 Recombinant DNA Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 description 44
- 239000012634 fragment Substances 0.000 description 44
- 235000013330 chicken meat Nutrition 0.000 description 43
- 241000588724 Escherichia coli Species 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 28
- 239000011800 void material Substances 0.000 description 27
- 238000002965 ELISA Methods 0.000 description 21
- 241000700605 Viruses Species 0.000 description 19
- 230000027455 binding Effects 0.000 description 19
- 108091034117 Oligonucleotide Proteins 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 16
- 230000008774 maternal effect Effects 0.000 description 13
- 230000001681 protective effect Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 108010076039 Polyproteins Proteins 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- 101001055979 Eumenes pomiformis Venom peptide 2a Proteins 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 239000006166 lysate Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 9
- 239000004365 Protease Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000002523 gelfiltration Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000003472 neutralizing effect Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003000 inclusion body Anatomy 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000005253 yeast cell Anatomy 0.000 description 6
- 108091033380 Coding strand Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 239000012506 Sephacryl® Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 210000002969 egg yolk Anatomy 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 3
- 101710194807 Protective antigen Proteins 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 101150093578 VP2 gene Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 101500001532 Avian infectious bursal disease virus Capsid protein VP2 Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108091029795 Intergenic region Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003413 degradative effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- 102220542331 39S ribosomal protein L15, mitochondrial_K315A_mutation Human genes 0.000 description 1
- 102220468378 ATP-dependent translocase ABCB1_K308A_mutation Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100313161 Caenorhabditis elegans mab-9 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101100532034 Drosophila melanogaster RTase gene Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 101001055968 Eumenes pomiformis Venom peptide 2b Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- YFNOUBWUIIJQHF-LPEHRKFASA-N Pro-Asp-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O YFNOUBWUIIJQHF-LPEHRKFASA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 244000053634 jackwood Species 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 102220081983 rs35405862 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108010082737 zymolyase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/72—Expression systems using regulatory sequences derived from the lac-operon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- IBDV Infectious Bursal Disease virus
- VN MAbs virus neutralizing mouse monoclonal antibodies
- a highly immunogenic form of the VP2 structural protein of IBDV which comprises a high molecular weight aggregated form of VP2 produced by expression of a nucleotide sequence coding for the VP2 structural protein or a polypeptide displaying the antigenicity of all or a part of the VP2 structural protein.
- the high molecular weight aggregated form of VP2 is produced by expression of an appropriate nucleotide sequence in yeast, for example in
- the nucleotide sequence is one which is expressed as a VP2 construct having a short N- terminal fusion, for example a construct in which the five N-terminal amino acids of native VP2 have been restored, or constructs in which these amino acids have been replaced by an octapeptide sequence such as MNSSSVPG (for construct expressed in E. coli) or MFSELDPQ (for construct expressed in yeast).
- MNSSSVPG for construct expressed in E. coli
- MFSELDPQ for construct expressed in yeast
- the present invention provides a vaccine composition for stimulating an immune response against IBDV, which comprises the highly immunogenic form of the VP2 structural protein of IBDV as described above, together with an acceptable carrier therefor.
- composition may also comprise an
- the invention also extends to a method for the preparation of this highly immunogenic form of VP2, which comprises expression of an appropriate nucleotide
- nucleotide sequence which is capable of being expressed as this highly immunogenic form of VP2.
- the five N-terminal amino acids of the VP2 molecule are not present in VP2 constructs such as clone PO described in International Patent Applications Nos. PCT/AU86/00156 and PCT/AU88/00206.
- Expression of the PO insert in certain E. coli expression vectors and yeast expression vector pAAH5 obtained from Dr. B.D.Hall, University of Washington, Seattle, U.S.A. which should give rise to unfused VP2, did not result in stable synthesis of VP2 protein.
- the minimum protective titres of maternal antibody in the circulation of progeny from hens vaccinated with recombinant VP2 were similar to those reported for maternal antibodies to whole IBDV (Fahey et. al. , 1987). This indicated that the protective ability of antibodies to recombinant VP2 were similar to antibodies to the original intact virus. Studies on the decline in the titre of maternal antibodies to recombinant VP2 in progeny chickens showed that it had a half life of 6 days, which is similar to that reported previously for the half life of antibodies to the original intact virus (Fahey et. al ., 1987).
- VP2 vaccine When recombinant VP2 vaccine was injected into adult hens which had previously been primed (sensitized) by exposure to the live virus, it induced an anamnestic serum antibody response, both of virus neutralizing and ELISA antibody.
- Figure 1 shows the construction of yeast and E. coli vectors for the expression of IBDV antigens.
- FIG. 1 Schematic representation of the IBDV polyprotein sequence in clone pEX.PO (described in PCT/AU86/00156). Square blocks depict repeats of the pentapeptide sequence AXAAS that occur four times in the polyprotein.
- B The vector pYELC5 employed for the copper inducible expression of foreign proteins in yeast.
- C Expression clones for the production of IBDV antigens, (i) clone pYELC5.P0 was constructed by inserting a Smal-PstI fragment (3.0 kb) encoding the IBDV polyprotein into pYELC5 cut with Pvull and Pstl.
- This construct has a yeast CZ7P2 transcription terminator but translation stops some 65 codons downstream from the second AXAAS. (v and vi)
- the missense translation in pYELC5.VP2J has been overcome by two strategies.
- pYELC5.VP2J has been cleaved with PstI and then the 3' overhanging ends have been removed by treatment with T4 polymerase in the presence of dNTPs. The religation of this produces pYELC5.VP2T (v) and in this vector
- Figure 2 shows the cloning strategy for the six yeast expression constructs described in Figure 1.
- Figure 3 shows Western blots of IBDV antigens produced by yeast transformants. Proteins were Western blotted in duplicate. Filter A was probed with anti-VP2 MAb 9/6 and filter B was probed with anti-VP3 MAb 17/80. The protein bands were visualized by reacting the filters with goat anti-mouse IgG horse radish peroxidase
- Proteins displayed are from yeast transformed with vectors pYELC5 (lane 1), pYELC5.PO (lane 2), pYELCR.PO ⁇ Xhol (lane 3), pYELC5.VP2T (lane 4) and from IBDV (lane 5).
- Pre-stained molecular weight markers are in lane M.
- the arrows pointing to filter A indicate the positions of VP2a (41 kDa) and VP2b (37 kDa), and the arrow pointing to filter B indicates the position of VP3 (32 kDa).
- the polypeptide bands (lane 2) larger than VP2a on filter A and VP3 on filter B respectively, represent incomplete cleavage of the precursor polyprotein expressed from the large genomic segment in clone pYELC5.PO.
- Figure 4 shows gel-filtration of pYELC5.P0 lysate on Sephacryl S.300 column.
- the top panel shows reactivity of column fractions with various MAbs; •—• anti-VP3 MAb 17/80; ⁇ — ⁇ VN MAb 9/6; ⁇ — ⁇ VN MAb 39A.
- the bottom panel shows the A 280 profile (solid line) and the amount of protein present in different fractions (•---•).
- Figure 5 shows gel-filtration of pTTQ18.VP2 lysate on Sephacryl S.300 column.
- the top panel shows
- FIG. 6 shows serum antibody responses of adult hens vaccinated with inactivated native VP2a/2b or either of two recombinant subunit vaccines. Groups of 4 hens were inoculated i.m. with either 20 ⁇ g VP2a/2b or 45 ⁇ g of either pYELC.5-PO or pYELC.5-VP2 in Freund's incomplete adjuvant. The recombinant proteins were the resuspended 40 K pellets from the S300 void volume fractions of 12 K supernates of each yeast cell lysate. A: ELISA titres; B: Virus neutralization titres.
- Figure 7 shows Western blot analyses of the VP2 present in the void volume (tubes 45-55) and included volume (tubes 81-90) fractions of yeast and E. coli lysates subjected to gel-filtration ( Figures 3 and 4).
- Samples analysed were: 1. pYELC5.PO; 2. pYELC5 PO ⁇ XhoI; 3.pYELC5.VP2T; 4. pTTQ18.VP2.
- a and b represent protein present in the void volume and included volume fractions, respectively.
- Filter A was probed with anti-VP2 MAb 9/6 and filter B was probed with anti-VP3 MAb 17/80.
- Figure 8 shows proteolytic activity (A 595nm ) of
- Figure 9 shows the cloning strategy for the
- Figure 10 shows agarose gel of PCR amplified DNA fragments.
- the molecular weight marker in well 10 is Drigest (Pharmacia). For the PCR amplification in wells 5 and 6 a different PCR buffer has been used than in wells 1 and 2.
- FIG. 11 shows construction and maps of plasmids.
- VP2 (of strain 002-73) was subcloned as a 1.5 kb Smal-Xbal fragment from plasmid pEX.PO ⁇ XhOl-Pstl into the Smal-Xbal sites of pTTQ18 (Amersham) to give pTTQ18-VP2.
- the small D ⁇ al-Sall fragment was then deleted to remove the lacZ ⁇ fragment and a
- VP2 is under control of the tac promoter and single stranded DNA can be obtained using M13 helper phage.
- the small SacI fragment of pIP201 containing the C-terminal half of VP2 has been replaced by the homologous fragment from pIP41.
- the VP2 hybrid protein consists of a N-terminal half from variant E fused to the C-terminal half from strain 002-73.
- T s gives rise to a VP2 hybrid consisting of the N-terminal half from strain 002-73 and the C- terminal half from variant strain E.
- Figure 12 shows dot blots of E. coli lysates with monoclonal antibodies.
- FIG. 14 shows the serum antibody response of two primed adult hens to 45 ⁇ g of pYELC5-VP2 in Freund's incomplete adjuvant. The serum was assayed for the titre of ELISA (A) and virus neutralizing (B) antibody.
- ISCOMS complexes
- the yeast constructs are shown in Fig.1C and the cloning strategy is set out in Fig.2.
- the VP2 expressed in Saccharomyces cerevisiae has been produced using the copper-inducible expression vector pYELC5 (see Fig.1B; Australian Patent Application 15845/88), and the
- Kluyveromyces lactis construct has been produced using the K. lactis vector E1 (kindly supplied by Dr. D. Clark- Walker, Australian National University, Canberra,
- lactis VP2T has the same insert as in pYELC5.VP2T.
- Western blots of the expression p;roducts probed with the anti-VP2 MAb 9/6, and anti-VP3 MAb 17/80 show (Fig.3) that the expression of the large genomic segment of IBDV (clone pYELC5.PO) in yeast results in the
- VP3 is not produced in clones pYELC5.PO ⁇ XhoI and pYELC5.VP2T because of the deletion of the VP4 and VP3 encoding regions (Fig.1).
- the VP2 molecule produced in pYELC5.PO ⁇ XhoI has an additional 12 KDa of irrelevant protein at the C-terminus and has a slower electrophoretic mobility than the correct-sized VP2 produced in clone pYELC5.VP2T in which a translation stop codon has been introduced at the C- terminus.
- the bands appearing below VP2a are degradation products.
- yeast-derived IBDV antigens were raised against the yeast-derived IBDV antigens by a single intramuscular injection of the yeast lysate, 12 K rpm supernatant, or column-derived fractions (equivalent in reactivity on serial dot blots with VN MAbs to 50 micrograms of viral VP2), in Freund's incomplete adjuvant into unprimed SPF chickens in duplicate. All the yeast constructs have in vitro antigenic properties identical to that of native VP2 and the E. coli construct
- the anti-VP3 MAb 17/80 reacts only with material from clone pYELC5.PO as this is the only clone which contains IBDV genetic material other than the VP2 gene.
- the reaction is confined to the void volume fractions.
- VN MAb 9 which recognizes undenatured and denatured VP2, reacts with both the void volume and included volume fractions of the yeast constructs
- pYELC5.PO (Fig.4), pYELC5.PO ⁇ XhoI, pYELC5.VP2T, K. lactis VP2T (result not shown), and the E. coli construct pTTQ18, VP2 (Fig.5).
- VN MAb 39A which only recognizes
- undenatured VP2 reacts predominantly with the void volume fractions from all the above constructs suggesting that more of the correctly-folded molecules are present in the void volume.
- both VP2 and VP3 are present in the void volume, and about 50% of the VP3 co-sediments with VP2 on high speed centrifugation. Void volume material immunoprecipitated with anti-VP3 MAb does not react with anti-VP2 MAbs on Western blots, and material precipitated with anti-VP2 MAb does not react with anti-VP3 MAb (results not shown). This would indicate that in pYELC5.PO, the VP2 and VP3 present in the void volume are not complexed to each other. The 40,000 rpm pellet of the void volume fraction of
- Electron micrographs of the void volume material do not show any defined particulate structures, but do form irregular dense bodies that specifically bind VN MAbs and immunogold particles (results not shown).
- yeast constructs were obtained with yeast cells treated with zymolyase to convert them to spheroplasts, followed by a brief
- proteases by gel-filtration or sedimentation.
- the presence of protease inhibitors such as PMSF and the lowering of pH during extraction may also be used to minimize degradation of VP2.
- the included volume fractions from the yeast constructs and E. coli pTTQ18.VP2 were non-immunogenic.
- Recombinant VP2 produced intracellularly in yeast is subject to proteolytic degradation, and the presence of some cellular proteins could lead to antigenic competition. It is, therefore, desirable to isolate the VP2 molecule in a form where it is both immunogenic and free of degradative proteases. Recombinant VP2 in yeast lysates is present in two forms - multimeric and
- the VP2 eluting in the void volume can be precipitated with 4% polyethylene glycol (PEG) 4000 2 C, 1 hour).
- the precipitate which can be recovered by low-speed centrifugation (2000 g x 10 min.), contains most of the VP2 activity (as assessed by reaction with MAb 39A) and is free of the majority of degradative proteases ( Figure 8).
- the monomeric form of VP2 eluting in the included volume is not precipitated at PEG concentrations of up to 10%.
- the multimeric and immunogenic form of VP2 can also be recovered from the yeast 3K supernatant (without prior gel-filtration) by precipitation with 4% PEG as described above. As can be seen in Figure 8, protease activity is precipitated in increasing quantities from the 3K
- oligonucleotides were synthesized in pairs as
- the constructs (p501 and p502) shown in Figure 9 were formed directly from this process. They have four nucleotides too many but are suitable candidates for restoration of the reading frames. This was achieved in two steps, the first by cleaving these constructs with Xmal .
- the endonuclease Xmal cleaves the recognition sequence in duplex DNA CCCGGG, leaving single stranded ends 5'CCGG. Such ends were readily removed by treatment with the exonuclease Mung Bean Nuclease (Pharmacia) according to the procedure described by New England
- DNA from p601 and p611 has been cloned into the yeast pAAH5 vector.
- the in-frame construct produces the polyprotein which is processed.
- the levels of VP2 synthesized are low (as expected from this non-regulated expression vector) but the VP2 appears stable unlike previously expressed VP2 using pAAH5.
- RNA of variant strain Delaware E (provided by Central Veterinary Laboratory, Weybridge, U.K.) was isolated from IBDV infected bursae as described previously (Azad et. al. , 1985). A yield of 1.5 mg RNA was obtained from 70 g of bursae. (b) Design of primers for cDNA synthesis and PCR amplification.
- DNA fragments suitable for subcloning were obtained by cDNA synthesis and polymerase chain reaction (PCR) amplification of E-strain sequences using the genomic RNA as template and synthetic oligonucleotides containing homologies to VP2 as primers. At the 5' end of the primers restriction sites had been incorporated to facilitate the subcloning of the amplified fragments.
- PCR polymerase chain reaction
- Genomic RNA was denatured by boiling followed by snap freezing and used as the template for the synthesis of the first strand of complementary DNA by reverse transcriptase from avian myoblastosis virus (AMV RTase, Pharmacia). The synthesis was primed either by
- Plasmid pIP207 was constructed to give a hybrid VP2 consisting of the N-terminal half from strain E and the C-terminal half from strain 002-73 fused at the VP2 internal Sad site. This was done by replacing the 1.4 kb SacI fragments of pIP201 with the corresponding fragment from pIP41 (Fig.11).
- the M13 subclones for DNA sequencing were obtained by ligating restriction fragments of pIP201 into the appropriate sites in M13mp18 and M13mp19.
- Plasmids were maintained in E. coli DH5 ⁇ (BRL) in LB medium containing 0.4% glucose and 100 ⁇ g/ml ampicillin.
- the expression of VP2 under the control of the Taq promoter was induced by growing for 2h in the same medium containing 0.5 mM IPTG but omitting glucose.
- the host protective antigen VP2 of variant strain E of IBDV has been cloned from genomic RNA using
- oligonucleotides complementary to conserved regions as primers for PCR.
- the amplification of the correct fragment was based on the finding that changes between strains 002-73 and E must have occurred in the middle of VP2 (Accl-Spel region) which forms the virus-neutralizing conformational epitope.
- the virus neutralizing MAb 39A does not recognise proteins of variant strain E.
- Sacl-Spel region of strain E containing the virus-neutralizing epitope has been sequenced and the resulting amino acid sequence was compared to the
- strain E substitution in strain E in the region of the second hydrophilic peak.
- the E strain also contained a new unique lVcol restriction site and had lost the Stul site present in 002-73 allowing the convenient discrimination between 002-73 and E strain DNA sequences,
- VP2 of pIP201 and pIP41 differ in their N- terminus (Table 7) which might contribute to a reduced expression level or reduced stability in pIP201. To solve the question whether this difference is important or whether the expression levels are the same in both plasmids and only the epitopes are altered and account for reduced binding, VP2 hybrid proteins between
- the hybrid VP2 produced by pIP211 is therefore a promising candidate for a recombinant IBDV vaccine against variant strain E.
- the hybrid VP2 from pIP211 has the same expression levels as the Australian strain 002-73 VP2 and contains the epitopes
- VP2 constructs contain a modified N terminus . Sequences corresponding to VP2 are printed bold. The numbers correspond to the residues in the native protein .
- VP2 of pIP41 begins with eight residues from the vector fused to residue 5Asp of VP2. In pIP201 six residues from the primer prec ede the Met start codon of VP2.
- Virus-neutralizing monoclonal antibodies recognise a conformation dependent discontinuous epitope within 145 amino acid residues in the middle of VP2 (Accl-Spel fragment) (PCT/AU88/00206). This fragment consists predominantly of very hydrophobic residues but also contains two small hydrophilic stretches close to either end. Previous studies involving deletion-expression analyses, suggested that the two hydrophilic peaks may be important determinants in the formation of the
- Variant strain E which is resistant to vaccination with serotype I inactivated vaccine and has lost the ability to bind to monoclonal antibody 39A specific for the virus-neutralizing conformational epitope proved to be valuable to identify the residues important for MAb 39A binding.
- Single amino acid substitutions and deletions were produced by oligonucleotide directed mutagenesis of a single-stranded DNA template obtained from phagemid vector pIP41 (or pIP201 for the back-mutation of VP2 from strain E). Mutations were generated with the "dut ung” method or by using the Amersham mutagenesis kit. Amino acid insertions were created by introducing linkers into the unique StuI site in pIP41.
- oligonucleotides used in the single amino acid substitutions were engineered so that they introduced new restriction sites into the plasmid to enable easy
- linker inserts were also screened by restriction enzyme digestion. All mutants were sequenced by double-stranded DNA sequencing to confirm the expected substitutions and insertions.
- the phenotype of the mutants was analysed using three different monoclonal antibodies (MAbs) 9/6, 39A and
- MAbs 9/6 and 39A recognise the 145 amino acid region of VP2.
- MAb6 binds to an area outside Accl-Spel at the C-terminal end of VP2 and was used to detect non-specific changes in the protein caused by the mutants.
- Residues in the second hydrophilic region close to the Spel site around aa 300-320 are also important for the formation of the conformational epitope.
- a 23 residue deletion in pIP77 led to the loss of binding to MAb 39A and 9/6, but not MAb 6/1.
- the conservative substitution Lys315Arg had no measurable effect on MAb binding.
- the MAb 39A which recognises the conformational epitope in VP2 of strain 002-73 does not recognise VP2 of variant strain E. Residues responsible for the
- the amino acid sequence of the AccI-Spel fragment of VP2 from variant strain E was compared with the corresponding fragment of the Australian strain 002-73. Between both strains only 14 residues are different in the 105 amino acid long Sacl-Spel fragment, and of those only two substitutions (317Asp and 322Glu in strain E compared with 317Gly and 322Asp in strain 002-73) occurred in the second hydrophilic peak (see previous Example 8, Table 8).
- the range of serum antibody levels in 10-15 chickens from each hen are shown in Table 12. All antibody titres were determined by ELISA. The mean titre of antibody in the egg yolk was half to one quarter that in the circulation of the donor hen, while the titre of antibody in the circulation of the hatched chickens was variable (Table 12). The antibody induced in the hens by the recombinant subunit IBD vaccines was transferred via the yolk to the progeny chickens.
- Table 13 shows that recombinant VP2 removed most of the ELISA antibody from antisera to native VP2a/2b and to pYELC.5-PO ⁇ XhoI. However, it removed a much smaller portion of the antibody to pYELC.5-PO.
- Virology 143 35-44. Azad, A.A., Jagadish, M.N., Brown, M.A. and Hudson, P.J. (1987). Virology 161: 145-152.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPJ446989 | 1989-05-30 | ||
AUPJ4469 | 1989-05-30 | ||
AU57315/90A AU643216B2 (en) | 1989-05-30 | 1990-05-29 | Production of IBDV VP2 in highly immunogenic form |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990015140A1 true WO1990015140A1 (en) | 1990-12-13 |
Family
ID=25631592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1990/000224 WO1990015140A1 (en) | 1989-05-30 | 1990-05-29 | Production of ibdv vp2 in highly immunogenic form |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0474676A4 (en) |
AU (1) | AU643216B2 (en) |
WO (1) | WO1990015140A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0481072A1 (en) * | 1990-05-04 | 1992-04-22 | University Of Maryland At College Park | Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines |
EP0517292A1 (en) * | 1991-05-27 | 1992-12-09 | SOLVAY (Société Anonyme) | Recombinant Avipox virus |
EP0755259A1 (en) * | 1994-03-29 | 1997-01-29 | University Of Maryland College Park | CHIMERIC INFECTIOUS BURSAL DISEASE VIRUS cDNA CLONES, EXPRESSION PRODUCTS AND VACCINES BASED THEREON |
WO2001092486A1 (en) * | 2000-05-31 | 2001-12-06 | Akzo Nobel N.V. | Serotype chimeric ibdv strains |
WO2002098921A1 (en) * | 2001-06-05 | 2002-12-12 | Commonwealth Scientific And Industrial Research Organisation | Recombinant antibodies against infectious bursal disease virus (ibdv) |
EP1523992A1 (en) * | 1996-07-19 | 2005-04-20 | Merial | Vaccine formulation against Gumboro disease |
WO2005049794A2 (en) | 2003-11-13 | 2005-06-02 | University Of Georgia Research Foundation, Inc. | Methods of characterizing infectious bursal disease virus |
WO2013107436A1 (en) * | 2011-12-13 | 2013-07-25 | Martin-Luther-Universität Halle-Wittenberg | Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens |
CN114891073A (en) * | 2021-10-28 | 2022-08-12 | 华南农业大学 | Soluble VP2 antigen, vaccine and preparation method of antigen |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5966886A (en) * | 1985-05-30 | 1986-12-24 | Commonwealth Scientific And Industrial Research Organisation | Expression of host-protective immunogens of ibdv. |
AU1990888A (en) * | 1987-06-26 | 1989-01-19 | Commonwealth Scientific And Industrial Research Organisation | Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies |
-
1990
- 1990-05-29 AU AU57315/90A patent/AU643216B2/en not_active Ceased
- 1990-05-29 WO PCT/AU1990/000224 patent/WO1990015140A1/en not_active Application Discontinuation
- 1990-05-29 EP EP19900908160 patent/EP0474676A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5966886A (en) * | 1985-05-30 | 1986-12-24 | Commonwealth Scientific And Industrial Research Organisation | Expression of host-protective immunogens of ibdv. |
AU1990888A (en) * | 1987-06-26 | 1989-01-19 | Commonwealth Scientific And Industrial Research Organisation | Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies |
Non-Patent Citations (7)
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0481072A1 (en) * | 1990-05-04 | 1992-04-22 | University Of Maryland At College Park | Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines |
EP0481072A4 (en) * | 1990-05-04 | 1993-06-09 | University Of Maryland At College Park | Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines |
EP0517292A1 (en) * | 1991-05-27 | 1992-12-09 | SOLVAY (Société Anonyme) | Recombinant Avipox virus |
CN1055501C (en) * | 1991-05-27 | 2000-08-16 | 戴米纳科有限公司 | Recombinant avipox virus, culture of cells infected by this virus and vaccines for poultry derived from this virus |
EP0755259A1 (en) * | 1994-03-29 | 1997-01-29 | University Of Maryland College Park | CHIMERIC INFECTIOUS BURSAL DISEASE VIRUS cDNA CLONES, EXPRESSION PRODUCTS AND VACCINES BASED THEREON |
EP0755259A4 (en) * | 1994-03-29 | 1999-12-22 | Univ Maryland | CHIMERIC INFECTIOUS BURSAL DISEASE VIRUS cDNA CLONES, EXPRESSION PRODUCTS AND VACCINES BASED THEREON |
JP2009149608A (en) * | 1996-07-19 | 2009-07-09 | Merial Sas | Polynucleotide vaccine preparation for bird |
EP1523992A1 (en) * | 1996-07-19 | 2005-04-20 | Merial | Vaccine formulation against Gumboro disease |
WO2001092486A1 (en) * | 2000-05-31 | 2001-12-06 | Akzo Nobel N.V. | Serotype chimeric ibdv strains |
US7449556B2 (en) | 2001-06-05 | 2008-11-11 | Commonwealth Scientific And Industrial Organisation | Recombinant antibodies against infectious bursal disease virus (ibdv) |
WO2002098921A1 (en) * | 2001-06-05 | 2002-12-12 | Commonwealth Scientific And Industrial Research Organisation | Recombinant antibodies against infectious bursal disease virus (ibdv) |
WO2005049794A2 (en) | 2003-11-13 | 2005-06-02 | University Of Georgia Research Foundation, Inc. | Methods of characterizing infectious bursal disease virus |
WO2013107436A1 (en) * | 2011-12-13 | 2013-07-25 | Martin-Luther-Universität Halle-Wittenberg | Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens |
KR20140105821A (en) * | 2011-12-13 | 2014-09-02 | 마르틴-루터-유니베르시태트 할레-비텐베르크 | Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens |
JP2015507472A (en) * | 2011-12-13 | 2015-03-12 | マーティン−ルター−ウニヴェアズィテート ハレ−ヴィッテンベアクMartin−Luther−Universitaet Halle−Wittenberg | Vaccination using recombinant yeast to generate a protective humoral immune response against a defined antigen |
CN104428417A (en) * | 2011-12-13 | 2015-03-18 | 哈雷-维滕贝格马丁-路德大学 | Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens |
RU2630620C2 (en) * | 2011-12-13 | 2017-09-11 | Мартин-Лютер-Университет Халле-Виттенберг | Vaccination by recombinant yeast with the formation of protective humoral immune response against specified antigens |
KR102027400B1 (en) * | 2011-12-13 | 2019-10-04 | 베로백신즈 게엠베하 | Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens |
US11065312B2 (en) | 2011-12-13 | 2021-07-20 | Verovaccines Gmbh | Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens |
CN114891073A (en) * | 2021-10-28 | 2022-08-12 | 华南农业大学 | Soluble VP2 antigen, vaccine and preparation method of antigen |
Also Published As
Publication number | Publication date |
---|---|
AU643216B2 (en) | 1993-11-11 |
EP0474676A1 (en) | 1992-03-18 |
AU5731590A (en) | 1991-01-07 |
EP0474676A4 (en) | 1993-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Macreadie et al. | Passive protection against infectious bursal disease virus by viral VP2 expressed in yeast | |
EP0755259B1 (en) | CHIMERIC INFECTIOUS BURSAL DISEASE VIRUS cDNA CLONES, EXPRESSION PRODUCTS AND VACCINES BASED THEREON | |
AU653387B2 (en) | Antigen-presenting chimaeric protein | |
Agterberg et al. | Outer membrane PhoE protein of Escherichia coli as a carrier for foreign antigenic determinants: immunogenicity of epitopes of foot-and-mouth disease virus | |
Azad et al. | Physicochemical and immunological characterization of recombinant host-protective antigen (VP2) of infectious bursal disease virus | |
JP2633457B2 (en) | How to prevent feline leukemia virus infection | |
JP2577280B2 (en) | Recombinant poxvirus and streptococcal M protein vaccine | |
AU643216B2 (en) | Production of IBDV VP2 in highly immunogenic form | |
US6054126A (en) | Cloning and expression of host-protective immunogens of IBDV | |
US5614409A (en) | Production of IBDV VP2 in highly immunogenic form | |
EP0500736B1 (en) | Recombinant vaccine for porcine pleuropneumonia | |
US5597570A (en) | Protein recognized by antibodies raised against native P28 of schistosoma mansoni | |
JP3023997B2 (en) | Recombinant Coccidiosis Vaccine-5-7 Eimeria Surface Antigen | |
JPH05509226A (en) | EHV-4 glycoprotein vaccine | |
HU217420B (en) | New immunogenic polypeptides, vaccines containing them and method for preparation and use of them | |
EP1334197B1 (en) | Yeast derived vaccine against ipnv | |
EP0614979B1 (en) | Hog cholera virus vaccine and diagnostic | |
EP0366684B1 (en) | Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies | |
JP3135060B2 (en) | Conjugate using partial fragment of outer membrane protein P2 of Haemophilus influenzae type b | |
US5273744A (en) | Vaccines for the protection of animals against theileria infection | |
AU619477B2 (en) | Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies | |
US5348866A (en) | Genes encoding porcine zona pellucida protein PZP-4, expression thereof and contraceptive vaccines comprising expressed (poly) peptides | |
CA2050275A1 (en) | Production of ibdv vp2 in highly immunogenic form | |
CA1339265C (en) | Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies | |
WO1989006971A1 (en) | Conserved rotavirus gene segments and use in immunization and neutralization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2050275 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990908160 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990908160 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990908160 Country of ref document: EP |